Celularity Inc 's Cash & cash equivalent grew by 59.24 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Celularity Inc 's Quick Ratio to 0.01, Quick Ratio remained below Celularity Inc average.

Within Major Pharmaceutical Preparations industry 503 other companies have achieved higher Quick Ratio than Celularity Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 4884, from total ranking in the first quarter 2026 at 5387.

Explain Quick Ratio?
How much Cash & cash equivalents CELU�s has?
What are CELU�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CELU/financial-strength

https://api.csimarket.com/api/v1/companies/CELU/fundamentals

https://api.csimarket.com/api/v1/companies/CELU/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CELU Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-13.71 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-32.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.01	Subscribe	Subscribe	Subscribe	Subscribe
CELU's Total Ranking	# 4884	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-28.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	59.24 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 504
Healthcare Sector	# 1026
Overall Market	# 5257

Quick Ratio Statistics
High	Average	Low
41.17	2.7	0
(Dec 31 2018)		(Jun 30 2021)

Financial Statements
Celularity Inc 's Current Liabilities	$ 60 Millions	Visit CELU's Balance sheet
Celularity Inc 's Cash & cash equivalent	$ 1 Millions	Visit CELU's Balance sheet
Source of CELU's Sales		Visit CELU's Sales by Geography

Cumulative Celularity Inc 's Quick Ratio

CELU's Quick Ratio for the trailling 12 Months

CELU Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	11.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	257.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.03	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4419	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-3.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-3.68 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CELU Financial Strength Comparisons >> Go to Compare CELU Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CELU's Current Liabilities to $59.74 millions, cumulative Quick Ratio to 0.03 below the CELU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 492 other companies have achieved higher Quick Ratio than Celularity Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 4772.

Explain Quick Ratio?
How much Cash & cash equivalents CELU�s has?
What are CELU�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 493
Healthcare Sector	# 1013
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.07	0.65	0.01
(Dec 31 2020)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
Celularity Inc	0.01	$ 0.586 Millions	$ 59.738 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions
Rain Enhancement Technologies Holdco Inc	0.01	$ 0.071 Millions	$ 13.574 Millions
IMPACT BIOMEDICAL INC.	0.00	$ 0.010 Millions	$ 2.045 Millions
Semnur Pharmaceuticals Inc	0.00	$ 0.039 Millions	$ 10.672 Millions
Cnbx Pharmaceuticals Inc	0.00	$ 0.010 Millions	$ 2.673 Millions
Accustem Sciences Inc	0.00	$ 0.013 Millions	$ 5.724 Millions

Date modified: 2026-10-21T15:15:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.